Synthesis, Antibacterial Activity and Molecular Docking Studies of New Pyrazole Derivatives

Author(s): Adnan Cetin*, Havva Kurt

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 6 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The pyrazole structure is an important heterocyclic structure and plays critical roles in agriculture, industrial and medicine. Furthermore, compounds containing pyrazole are known to exhibit various biological properties such as antibacterial, antifungal, anticancer, antiinflammatory, antidepressant, antipyretic, antiviral, anti-tubercular and anti-HIV activities. Because of these properties, pyrazole molecules have become a very popular topic for organic chemists.

Methods: A series newly substituted pyrazole molecules were synthesized and characterized. Their antimicrobial activities were investigated by disk diffusion method against some gram positive bacteria and gram negative bacteria.

Results: The present results indicated that the some test compounds were active in a broad spectrum against important human pathogenic microorganisms. The substituted pyrazoles including carbazone (7a, b) and thiazolidine (8a, b) showed a wide variety of biological activities. The results showed that synthesized pyrazole, compounds 7b and 8b are highly active and more potent in both biological and molecular docking simulation studies.

Conclusion: The synthesized pyrazole molecules showed moderate antibacterial activities against the tested microorganism compared to antibiotic drug. Some test compounds (7b and 8b) might be used as new antibacterial agents.

Keywords: Binding energy, biologic activity, in silico, ligand efficient, semicarbazide, thiazolidine.

[1]
Nadkarni, S.; LaJoie, J.; Devinsky, O. Current treatments of epilepsy. Neurology, 2005, 64(12)(Suppl. 3), S2-S11.
[http://dx.doi.org/10.1212/WNL.64.12_suppl_3.S2] [PMID: 15994220]
[2]
Shakirullah Ali, N.; Khan, A.; Nabi, M. The Prevalence, incidence and etiology of epilepsy. Int. J. Clin. Exp. Neurol., 2014, 2, 29-39.
[3]
Schmidt, D.; Sillanpää, M. Evidence-based review on the natural history of the epilepsies. Curr. Opin. Neurol., 2012, 25(2), 159-163.
[http://dx.doi.org/10.1097/WCO.0b013e3283507e73] [PMID: 22274775]
[4]
Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82.
[http://dx.doi.org/10.1038/nrd2997] [PMID: 20043029]
[5]
Balasubramanian, D.; Deng, A.X.; Doudney, K.; Hampton, M.B.; Kennedy, M.A. Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line. Neuropharmacology, 2015, 99, 79-88.
[http://dx.doi.org/10.1016/j.neuropharm.2015.06.018] [PMID: 26151765]
[6]
Engel, J., Jr Approaches to refractory epilepsy. Ann. Indian Acad. Neurol., 2014, 17(Suppl. 1), S12-S17.
[http://dx.doi.org/10.4103/0972-2327.128644] [PMID: 24791078]
[7]
Aurlien, D.; Gjerstad, L.; Taubøll, E. The role of antiepileptic drugs in sudden unexpected death in epilepsy. Seizure, 2016, 43, 56-60.
[http://dx.doi.org/10.1016/j.seizure.2016.11.005] [PMID: 27886630]
[8]
Chong, D.J.; Lerman, A.M. Practice update: review of anticonvulsant therapy. Curr. Neurol. Neurosci. Rep., 2016, 16(4), 39.
[http://dx.doi.org/10.1007/s11910-016-0640-y] [PMID: 26984292]
[9]
Bialer, M. New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther. Drug Monit., 2002, 24(1), 85-90.
[http://dx.doi.org/10.1097/00007691-200202000-00015] [PMID: 11805728]
[10]
Faizi, M.; Dabirian, S.; Tajali, H.; Ahmadi, F.; Zavareh, E.R.; Shahhosseini, S.; Tabatabai, S.A. Novel agonists of benzodiazepine receptors: design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo[1,5-a]pyrimidinone and 3-amino-1,2,4-triazole derivatives. Bioorg. Med. Chem., 2015, 23(3), 480-487.
[http://dx.doi.org/10.1016/j.bmc.2014.12.016] [PMID: 25564376]
[11]
Krall, R.L.; Penry, J.K.; White, B.G.; Kupferberg, H.J.; Swinyard, E.A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia, 1978, 19(4), 409-428.
[http://dx.doi.org/10.1111/j.1528-1157.1978.tb04507.x] [PMID: 699894]
[12]
Porter, R.J.; Cereghino, J.J.; Gladding, G.D.; Hessie, B.J.; Kupferberg, H.J.; Scoville, B.; White, B.G. Antiepileptic Drug Development Program. Cleve. Clin. Q., 1984, 51(2), 293-305.
[http://dx.doi.org/10.3949/ccjm.51.2.293] [PMID: 6380818]
[13]
White, H.S.; Woodhead, J.H.; Wilcox, K.S.; Stables, J.P.; Kupferberg, H.J.; Wolf, H.H. In Antiepileptic Drugs, 5th; Lippincott Williams & Wilkins Publishers: New York, 2002, pp. 36-48.
[14]
King, E.J.; Armstrong, A.R. A convenient method for determing serum anf bile phosphatase activity. Can. Med. Assoc. J., 1934, 31(4), 376-381.
[PMID: 20319659]
[15]
Gokani, V.N.; Thakker, M.U.; Patel, J.G.; Ghosh, S.K.; Chatterjee, S.K. Thin-layer chromatographic method for estimation of gamma-aminobutyric acid from brain. Indian J. Physiol. Pharmacol., 1979, 23(2), 101-104.
[PMID: 489090]
[16]
Zhang, H.J.; Shen, Q.K.; Jin, C.M.; Quan, Z.S. Synthesis and Pharmacological Evaluation of New 3,4-Dihydroisoquinolin Derivatives Containing Heterocycle as Potential Anticonvulsant Agents. Molecules, 2016, 21(12)E1635
[http://dx.doi.org/10.3390/molecules21121635] [PMID: 27916842]
[17]
Zhang, M.M.; Wang, X.S.; Li, Q.; Yao, C.S.; Tu, S.J. Three-Component One-Pot Synthesis of 1-Aryl-4-benzo[f]quinoline Derivatives in Aqueous Media. Youji Huaxue, 2008, 28, 881-884.
[18]
Allinger, N.L. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc., 1977, 99, 8127-8134.
[http://dx.doi.org/10.1021/ja00467a001]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 6
Year: 2020
Page: [745 - 756]
Pages: 12
DOI: 10.2174/1570180816666190905155510
Price: $65

Article Metrics

PDF: 12